Please login to the form below

Not currently logged in
Email:
Password:

AZ reacts to SMC's decision on Iressa

UK drug manufacturer expresses disappointment following the SMC's decision not to recommend Iressa for use in NHS Scotland

AstraZeneca (AZ) UK has expressed disappointment following the Scottish Medicines Consortium's (SMC) decision not to recommend Iressa (gefitinib) for use in NHS Scotland for the first line treatment of advanced NSCLC in patients with EGFR mutation positive tumours.

The drug manufacture claims that the SMC's negative decision creates inequality north of the border as patients in England and Wales are able to access gefitinib on the NHS following the positive recommendation of gefitinib by the National Institute for Health and Clinical Excellence (NICE) in July 2010.

Despite the Patient Access Scheme Assessment Group (PASAG) approving the Single Payment Access (SPA) scheme put forward by AZ in Scotland, the SMC rejected the submission for gefitinib on the grounds of cost. AZ submitted a £14,210 cost per QALY, but the SMC based its decision on the assumption that the cost per QALY is likely to be over £30,000. 

The SMC's decision does not question the clinical effectiveness of gefitinib, as it recognised in its original decision in May 2010 that gefitinib, a targeted oral therapy, offers significant advantages to people with NSCLC over traditional treatment with doublet chemotherapy, in terms of improved Progression-Free Survival (PFS), improved quality of life (QoL) and symptom control.    

NHS boards will be able to take up the patient access scheme for any patients accessing gefitinib through Individual Patient Treatment Requests (exceptional use).

13th December 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics